Evaluation oncotype DX<sup>®</sup> 21‐gene recurrence score and clinicopathological parameters: a single institutional experience

Ayat Lashen(University of Nottingham), Emad A. Rakha(Nottingham University Hospitals NHS Trust), Michael S. Toss(Nottingham City Hospital), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Wakkas Fadhil(University of Nottingham), Georgette Oni(Nottingham University Hospitals NHS Trust)

Histopathology

January 12, 2023

10.1111/his.14863

Cited by 25

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

|New England Journal of Medicine|2010|4.5k

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

|The Lancet|2022|664

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

|The Lancet Oncology|2013|605

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

|The Lancet Oncology|2014|374

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

|The Lancet Oncology|2015|282